by Shana Cristoferi | Mar 18, 2020 | IMV Inc., News
See original release here FOR IMMEDIATE RELEASE Dartmouth, Nova Scotia, March 18, 2020 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based...
by Shana Cristoferi | Feb 25, 2020 | IMV Inc., News
See original release here February 25, 2020 at 3:05 AM EST First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor 79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions 37% achieved...
by administrator | Jan 17, 2019 | IMV Inc., Members, News
Read original release here January 17, 2019 at 7:05 AM EST DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the...
by administrator | Sep 4, 2018 | IMV Inc., News
See original article here DARTMOUTH, Nova Scotia, Sept. 04, 2018 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, celebrated its grand opening today of its new facilities in Dartmouth, Nova Scotia. Frederic Ors,...
by administrator | Jun 1, 2018 | IMV Inc., News
See original story here HALIFAX, Nova Scotia, May 31, 2018 (GLOBE NEWSWIRE) — IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVD), a clinical stage immunotherapy company, today announced that its common shares have been approved for listing on...
